GYNECOLOGIC CANCERS

The phase 3 LEAP-001 trial did not meet its primary end points of overall survival and progression-free survival.

The FDA has granted priority review to the supplemental biologics application of mirvetuximab soravtansin-gynx for the treatment of patients with platinum-resistant ovarian cancer.

Olvimulogene nanivacirepvec, an oncolytic viral-based therapy, has earned a fast track designation from the FDA in ovarian cancer resistant or refractory to platinum-based chemotherapy.

Bradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

The combination of tumor-infiltrating lymphocytes and chemotherapy showed a robust response rate and improvements in progression-free survival in a phase 1/2 study.

Findings from a phase 1 trial shows the early promise of an ENB-003 and pembrolizumab regimen for the treatment of platinum refractory or resistant ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bradley Corr, MD, discussed the use of immune checkpoint inhibitors in patients with advanced endometrial cancer. This is the second of 2 articles based on this event.

Selinexor maintenance therapy shows potential in bettering survival compared with placebo in patients with TP53 wild-type recurrent or advanced endometrial cancer.

Findings from the phase 2 RAMP 201 trial show avutometinib plus defactinib demonstrates robust efficacy in patients with recurrent low-grade serious ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul A. DiSilvestro, MD, discussed with participants concerning the management of adverse events in a patient receiving single-agent immune checkpoint inhibitor for advanced mismatch-repair deficient endometrial cancer.

Retrospective data shows that a multidisciplinary surgical approach may improve survival in patients with ovarian cancer.

The combination of dostarlimab and chemotherapy demonstrated meaningful improvements in overall survival for the treatment of primary advanced or recurrent endometrial cancer, according to findings from the phase 3 RUBY trial.

During a Targeted Oncology™ Case-Based Roundtable™ event, David M. O'Malley, MD, discussed with participants their experiences with using PARP inhibitors in patients with advanced ovarian cancer.

In an interview with Targeted Oncology, Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.

Tisotumab vedotin-tftv improved survival in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

CLN-619 has emerged for the treatment of advanced solid tumors in the clinical trial setting. Early results are promising, says lead investigator Judy Wang, MD

Dr Matthew A. Powell shares some closing thoughts on emerging agents and combination therapies in the endometrial cancer treatment landscape.

Matthew A. Powell, MD, reviews key takeaways from the Study-309/KEYNOTE-775 trial investigating lenvatinib plus pembrolizumab for the treatment for endometrial cancer.

Dr Matthew A. Powell details the rationale for using single-agent immunotherapy treatments for patients with advanced or recurrent endometrial cancer with reference to data updates from several key clinical trials.

Matthew A. Powell, MD, shares an overview of the systemic treatment options for patients with relapsed or metastatic endometrial cancer and the factors he considers when selecting an appropriate frontline therapy.

Dr Matthew A. Powell reviews the study design and key endpoints of the RUBY trial in dMMR endometrial cancer and explains the potential clinical implications of the data.

Medical expert provides an overview of the recommended biomarker testing for endometrial cancer and the frontline treatment options available for patients with dMMR/MSI-high endometrial cancer.

The first randomized study of immune checkpoint inhibitor therapy in platinum-sensitive ovarian cancer has missed its key end point.

Ruchi Garg, MD, discusses the impact of targeted therapies studies in patients with early and recurrent endometrial cancer.

John Diaz, MD, discusses some known biomarkers in ovarian cancer and where he hopes to see more research in the future.